PROK
PROKIDNEY CORP.
NASDAQ · Healthcare · Biotechnology · US
$1.30
−11.90%Oct 29, 2026, 21:59 UTC
PROKIDNEY CORP. entered into an at-the-market sale agreement with JEFFERIES LLC to offer up to $200 million of its Class A common stock, with Jefferies receiving compensation of up to 3.0% of gross proceeds.
Oct 22, 2026, 12:45 UTC
ProKidney announced that it will host a virtual key opinion leader event on October 27, 2026, at 10:30 a.m. ET.
Source:Oct 22, 2026, 12:00 UTC
ProKidney announced that it will present eight abstracts, including one oral presentation, at the AMERICAN SOCIETY OF NEPHROLOGY, Inc.'s PROKIDNEY CORP. 2026 in Denver from October 21 to 25.
Source:Oct 2, 2026, 13:00 UTC
ProKidney Corp. announced that eight abstracts, including one oral presentation, were selected for presentation at the American Society of Nephrology's Kidney Week 2026, to be held October 21-25, 2026, in Denver, Colorado.
Source:Aug 10, 2026, 22:56 UTC
ProKidney Corp. reported a second-quarter loss of $0.15 per share, missing the Zacks Consensus Estimate of a $0.13 loss and matching the year-ago loss of $0.13 per share.
Source: